Imagine a delivery truck that can only drop off packages at one specific house without getting stopped by security. Most current gene therapy 'trucks' are based on natural viruses that the body's immune system recognizes and blocks. This project builds a custom, stripped-down version of a virus from scratch using computers to ensure it reaches the heart or brain safely and effectively.
Current gene therapy vectors are often recognized by the immune system or fail to reach the specific target organ, leading to low efficacy and failed clinical outcomes in heart and brain treatments.
A platform for in silico-designed adenovirus vectors and a bank of 'iAd-Zero' prototypes stripped of unwanted elements for specific organ targeting.
If you are a gene therapy developer dealing with low delivery efficiency in the brain—this project developed in silico-designed intelligent adenovirus vectors that target specific cell surface proteins. This allows for more precise transgene expression in neurodegenerative disorders.
If you are a CDMO dealing with the difficulty of scaling complex viral vectors—this project developed a bank of 'iAd-Zero' prototypes designed for production potential. This ensures a smoother transition from lab design to clinical manufacturing.
If you are a research firm dealing with the inability to target heart muscle cells effectively—this project developed vectors that have been screened for efficacy to transduce heart muscle cells in vitro. This provides a platform for treating cardiovascular diseases with higher precision.
Based on available project data, there is no specific pricing or cost information provided for the iAds vectors.
The project includes SME and pharma manufacturing partners to allow seamless clinical translation and considers production potential during the in silico design phase.
The project mentions a 'proprietorial adenovirus type' used to create the bank, but specific licensing terms are not detailed in the provided text.
The project period runs from 2023-05-01 to 2027-04-30, suggesting the platform development phase concludes in early 2027.
The vectors act as the delivery system (the 'truck') for transgenes, designed to overcome host responses and imperfect targeting that usually stunt long-term expression.
The consortium is well-balanced for translation, consisting of 9 partners across 6 countries. With a 22% industry ratio (including 2 industry partners and 1 SME), the project bridges the gap between 4 universities and 3 research organizations, ensuring that the in silico designs are grounded in manufacturing reality.
Contact CNRS (France) regarding the iAd-Zero prototype bank.
Request a technical briefing on iAd-Zero targeting capabilities.
